At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Switzerland based CFO’ operating in the Pharmaceutical space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
CFO of NovImmune
Andrew J. Oakley joined Novimmune as Chief Financial Officer in March 2014, bringing with him over 30 years of professional experience in pharmaceutical, financial, and industrial organizations. Previously, Andrew served for ten years as Executive Vice President and Chief Financial Officer at Actelion Ltd., a global biopharmaceutical leader headquartered in Switzerland. During his tenure there, Andrew led the financial functions of the company as it grew from 200 employees with sales of CHF 100 million into a global enterprise with 2,500 employees and sales of CHF 1.7 billion. The company’s market capitalization also multiplied from CHF 1.5 billion to CHF 7.5 billion during that time. Prior to Actelion, Andrew was a senior finance executive with Accenture, the global business consultancy, and held a number of additional senior management and finance roles at financial and industrial organisations in Australia, the UK and the US. An Australian citizen, Andrew Oakley holds a Bachelor of Economics from Macquarie University in Sydney and an MBA from the London Business School. He also holds an ACA qualification from the Australian Institute of Chartered Accounting.
Follow Andrew Oakley:
About Autolus, NovImmune: NovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.
Chief Financial Officer of Allecra Therapeutics
Andrew has over 30 years’ experience in finance within the pharma and medical device industry as well as in public accounting. He served as Vice President Finance and Chief Financial Officer of Sucampo Pharmaceuticals Inc between 2011 – 2017 and has held other management positions with a number of other companies within Europe, Asia and USA. He is a Fellow of the Institute of Management Accountants and a Chartered Global Management Accountant and has studied business and accounting at Liverpool John Moore’s University and Durham University Business School.
Follow Andrew Smith:
About Allecra Therapeutics: Allecra is a biopharmaceutical company focused on the development of novel treatments to combat multi-drug-resistant bacterial infections.
CFO of Strekin
URS BREITENSTEIN CHIEF FINANCE OFFICER Dr. Urs Breitenstein supports companies and investors with his corporate transactions, financing or valuation expertise and with his network. As a partner of Hoffmann & Co AG, a Swiss M&A and CFO services company, he is involved with several startups and growth companies in the life science sector as interim or part time CFO, as business advisor or as a board As a board member, he also represents an investment company. Urs previously served for more than ten years as a team leader and partner at international professional service firms (PwC, Deloitte) providing valuation, corporate finance and M&A services. He supported many large and mid-sized life science (but also manufacturing and service sector) transactions in Switzerland and in Europe. He is a graduate of the postgraduate study centre of the Swiss National Bank at Gerzensee and holds a doctorate in economics from the University of Basel.
Follow Urs Breitenstein:
About Hoffmann & partner, Kinarus AG, Strekin, Versameb: Strekin AG is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland.
CFO of Advanced Accelerator Applications
Heinz Mäusli joined AAA in 2003. He also serves as a member of the boards of directors of several of AAA’s subsidiaries. Prior to joining AAA, Mr. Mäusli was a management consultant for Accenture from 1996 to 2001 and Gemeni Consulting from 1995 to 1996. Mr. Mäusli has a master degree from the University of St. Gallen and a master in business administration from Columbia Business School.
Follow Heinz Mausli:
About Advanced Accelerator Applications: AAA is an innovative medicines company focused on the development of targeted radioligand therapies and precision imaging radioligands.
Chief Businesss Officer, CFO and Board Member of NETRIS Pharma
Follow Christophe Guichard:
About ArisGen, Eclosion SA, NETRIS Pharma: NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the pharmaceutical industry.
CFO of Siegfried Holding
Reto Suter serves as the Chief Financial Officer of the Siegfried Group.
Follow Reto Suter:
About Siegfried Holding: Siegfried Holding is a pharmaceutical company that offers and manufactures primary and secondary drug substances and products.